Search results

Skip to results

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 16 to 21 of 21 results for gefitinib

  1. Lung cancer (non-small cell) - afatinib [ID357]

    Discontinued Reference number: GID-TAG422

    Technology appraisal guidance
    Discontinued

  2. Ramucirumab for previously treated locally advanced or metastatic non-small-cell lung cancer (TA403)

    Evidence-based recommendations on ramucirumab (Cyramza) for locally advanced or metastatic non-small-cell lung cancer in adults who have had platinum-based chemotherapy.

    Technology appraisal guidance
    Published
    24 August 2016
    View recommendations

    Sections for TA403

  3. Atezolizumab for treating locally advanced or metastatic non-small-cell lung cancer after chemotherapy (TA520)

    Evidence-based recommendations on atezolizumab (Tecentriq) for locally advanced or metastatic non-small-cell lung cancer after chemotherapy in adults.

    Technology appraisal guidance
    Published
    16 May 2018
    View recommendations

    Sections for TA520

  4. Treatments for non-small-cell lung cancer [ID6234]

    Discontinued Reference number: GID-TA11289

    Technology appraisal guidance
    Discontinued

  5. Gefitinib for the second-line treatment of locally advanced or metastatic non-small-cell lung cancer (terminated appraisal) (TA175)

    This guidance has been updated and replaced by NICE technology appraisal guidance 374.

    Withdrawn guidance

  6. Plasma EGFR mutation tests for adults with locally advanced or metastatic non-small-cell lung cancer (MIB137)

    NICE has developed a medtech innovation briefing (MIB) on plasma EGFR mutation tests for adults with locally advanced or metastatic non-small-cell lung cancer .

    Medtech innovation briefing
    Published
    18 January 2018